Marijuana Justice Act of 2017 may not become law, but it advances the national debate. Senator Cory Booker, sponsored the Marijuana Justice Act of 2017
Marijuana has been used both medicinally and recreationally since ancient times and interest in its compounds for pain relief has increased in recent years. The identification of our own intrinsic, endocannabinoid system has laid the foundation for further research. Phytocannabinoids have been identified as key compounds involved in analgesia and anti-inflammatory effects. Other compounds found in cannabis such as flavonoids and terpenes are also being investigated as to their individual or synergistic effects.
Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study.
Cannabis use is associated with reduced prevalence of obesity and diabetes mellitus (DM) in humans and mouse disease models. Among cannabis users, dependent patients had 43% significantly lower prevalence of NAFLD compared to non-dependent patients (AOR: 0.57[0.42-0.77]; p<0.0001). Our observations suggest that cannabis use is associated with lower prevalence of NAFLD in patients. These novel findings suggest additional molecular mechanistic studies to explore the potential role of cannabis use in NAFLD development.
Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients.
Medical cannabis is increasingly being used for a variety of health conditions as more states implement legislation permitting medical use of cannabis. Little is known about medical cannabis use patterns and motives among adults across the lifespan.The present study examined data collected at a medical cannabis dispensary in San Francisco, California. Participants included 217 medical cannabis patients who were grouped into age-defined cohorts (younger: 18-30, middle-aged: 31-50, and older: 51-72). The age groups were compared on several measures of cannabis use, motives and medical conditions using one-way ANOVAs, chi-square tests and linear regression analyses.
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial.
Twenty patients aged 18-75 years with a Crohn’s disease activity index (CDAI) >200 were randomised to receive oral (10 mg) CBD or placebo twice daily. Patients did not respond to standard treatment with steroids (11 patients), thiopurines (14), or TNF antagonists (11). Disease activity and laboratory parameters were assessed during 8 weeks of treatment and 2 weeks thereafter. Other medical treatment remained unchanged.In this study of moderately active Crohn’s disease, CBD was safe but had no beneficial effects. This could be due to lack of effect of CBD on Crohn’s disease, but could also be due to the small dose of CBD, the small number of patients in the study, or the lack of the necessary synergism with other cannabinoids. Further investigation is warranted.
There were 120 patients. Twenty nine were women and 91 were men. Patients testing positive for THC-COOH had a shorter length of stay compared to patients testing negative for THC-COOH, after adjusting for age, prior psychiatric admissions, history of a psychotic-spectrum disorder, and comorbid additional substance use (p = 0.02). There were no differences in 30-day readmissions, 30-day post-discharge presentation to the Denver Health psychiatric emergency department, BPRS scores, and medication administration.
There are some indices that legalisation of medical cannabis in the Republic of Serbia might be considered. The purpose of this research was to assess knowledge and attitudes towards medical cannabis in an urban adult population. This cross-sectional study was conducted in December 2015 and January 2016. A convenience sample of study participants comprised users of the Community Health Centre. A total of 360 adults were invited to participate. Data were collected through an anonymous questionnaire.
You’ve probably heard this before.
As early as 2008, several reports, including one published in Molecular Pharmaceutics, began proposing various therapeutic pathways by which cannabinoids could treat Alzheimer’s Disease patients, but none were proven.
When I got given the Dairy Queen to test there were 2 very distinct phenotype`s. The 1st pheno was very cheese dominant, with a nice compact, tight bud structure, very dense hard buds, still very sticky to the touch (after a 8 week cure) and a real nice amount of trichomes which when looked at under a 100x scope were 35% amber/60%cloudy/5%clear. Phenotype 2 had a much more fluffy texture with still nice chunky buds bud not as hard and dense as pheno 1
Dutch Dragon (Paradise Seeds): Sweet is the breath of the dragon! Words & Photos: Green Born Identity – G.B.I.
The Doc was happy to grow a longtime classic and bestseller of Paradise Seeds: Dutch Dragon a mostly sativa strain with South African pedigree.